Pharma Industry

The 17th edition of the CPHI and PMEC expo showcasing the pharmaceutical industry's modernisation, innovation and sustainability will be held from November 26 to 28 in Greater Noida. The expo will this year offer a pivotal marketplace for over 2,000 exhibitors to engage with anticipated participation from countries, including the US, UAE, South Korea, Japan, Egypt, Vietnam, the Philippines, Malaysia, Italy, Sri Lanka, Bangladesh, Nepal, Iran, and the United Kingdom. The expo will showcase over 10,000 products, offering a unique space for collaboration and innovation in the pharma industry, said a release from the organiser Informa Markets in India. The noteworthy exhibitors include Dr Reddy's Laboratories Ltd, Biocon Ltd, Glenmark Lifesciences Ltd, Morepen Laboratories Ltd, Hetero Labs Limited, Lupin Ltd, Signet Excipients Pvt. Ltd, MSN Laboratories Pvt. Ltd, Sekhmet Pharmaventures Pvt. Ltd, Tirupati Lifesciences Pvt. Ltd, Merck Life Science Pvt. Ltd. and many others, the statement

AstraZeneca Pharma India on Wednesday said its net profit declined by 27 per cent on-year to Rs 38 crore in the second quarter ended on September 30, 2024. The drug firm reported a net profit of Rs 52 crore in the July-September quarter of last fiscal. Revenue from operations stood at Rs 408 crore for the period under review compared with Rs 311 crore in the year-ago period, the firm said in a regulatory filing. Shares of the company ended 3.74 per cent lower at Rs 7,133.10 apiece on the BSE.

The value growth comes at a time when the IPM has registered a negative volume growth of 1.8 per cent

The company is still 'evaluating' the price of the drug, but is confident that the price-sensitive Indian population will be able to afford it, Novo's India Managing Director Vikrant Shrotriya said

Shreehas Tambe, MD & CEO, Biocon Biologics talks about refinancing, upcoming launches, and future roadmap, in a virtual interaction

Cipla eyes growth in the Indian and US markets with upcoming launches

The company launched 14 new products in India this quarter

The decline in PAT can be partly attributed to the deferred tax credit of Rs 21 crore, which the company received in the year-ago quarter

Drug firm Lupin on Monday said it has appointed Claus Jepsen as President, Global Specialty business. Jepsen joins Lupin from Takeda Pharmaceuticals, where he led the Global Strategy for rare diseases. "His experience in leading specialty strategy, commercial planning and portfolio choices across key markets will enable us to build our Specialty brand business," Lupin CEO Vinita Gupta said.

The drug, Hympavzi, is given under the skin through an auto-injector pen to prevent or reduce bleeding episodes in hemophilia A or B patients aged 12 years and older

The concluding part of the series delves into strategies being applied by leading drug firms to battle counterfeits

Aurobindo Pharma on Monday said the US health regulator has issued 10 observations after inspecting the API facility of its subsidiary in Telangana. The US Food and Drug Administration (USFDA) inspected Unit-II, an active pharmaceutical ingredients (API) manufacturing facility of Apitoria Pharma, a wholly-owned subsidiary of the company, in Sangareddy district from September 23-27, 2024, the Hyderabad-based drug maker said in a regulatory filing. The inspection closed with 10 observations, it added. The observations are procedural in nature and will be responded to within the stipulated time, the drug maker stated. Shares of Aurobindo Pharma on Monday ended 3.16 per cent down at Rs 1,462 apiece on BSE.

Move comes after drug regulator had suspended nod granted to firm to manufacture, sell PresVu eye drops

FTVC has developed a "MicroLab", an open-source controlled lab reactor (CLR) made from components easily available online

Akums Drugs and Pharmaceuticals on Friday said it has received patent for a formulation for Sickle Cell Disease (SCD). The company has received a patent from India patent office for its room temperature stable oral suspension of Hydroxyurea, a formulation aimed at managing SCD. "Our constant endeavor is to work on affordable medicines for Orphan Drugs and reduce dependency on imported medicines ensuring patient safety from rare diseases with timely and necessary treatment," Akums Managing Director Sanjeev Jain said in a statement. SCD, a genetic blood disorder, leads to severe health complications such as anaemia, frequent pain episodes and other debilitating symptoms, affecting millions worldwide, especially in India and Africa. Akums said its formulation will come at a fraction of the cost of imported Hydroxyurea solution.

Shares of Jubilant Pharmova surged 12 per cent on the BSE in Friday's intra-day trade to hit a new high of Rs 1,169.55, in an otherwise subdued market.

More than 31 million equity shares, representing 12.89 per cent equity of the pharmaceutical company, had changed hands on the NSE till 02:08 PM.

Shares of Sudarshan Pharma Industries were frozen in upper circuit of 5 per cent at Rs 274.50, which is also the new high it hit on the BSE in Thursday's intra-day trade.

Sheetal Sapale, vice-president (commercial) at Pharmarack, said that new introductions and price growth have driven the market growth for the month of August 2024

Entod Pharmaceuticals on Tuesday said it has received approval from the Drug Controller General of India (DCGI) to market eye drops for the treatment of presbyopia. The Mumbai-based drugmaker has received a final approval for PresVu eye drops and plans to introduce it in the domestic market in the first week of October. The approval follows an earlier recommendation by the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO). PresVu is the first eye drop in India specifically developed to reduce dependency on reading glasses for individuals affected by presbyopia, a common age-related vision condition that typically impacts those over 40. "This DCGI approval is a major step forward in our mission to transform eye care in India. PresVu is more than just a product; it's a solution that stands to improve the lives of millions by offering them greater visual independence," Entod Pharmaceuticals CEO Nikkhil K Masurkar said. According to industry ...